Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 189

1.

CNTO 530 increases expression of HbA and HbF in murine models of β-thalassemia and sickle cell anemia.

Makropoulos DA, Achuthanandam R, Avery J, Wilson K, Brosnan K, Miller A, Nesspor T, Chroscinski D, Walker M, Egenolf D, Huang C, Bugelski PJ.

Curr Pharm Biotechnol. 2013;14(2):242-8.

2.

Augmentation by erythropoietin of the fetal-hemoglobin response to hydroxyurea in sickle cell disease.

Rodgers GP, Dover GJ, Uyesaka N, Noguchi CT, Schechter AN, Nienhuis AW.

N Engl J Med. 1993 Jan 14;328(2):73-80.

3.

A short-term trial of butyrate to stimulate fetal-globin-gene expression in the beta-globin disorders.

Perrine SP, Ginder GD, Faller DV, Dover GH, Ikuta T, Witkowska HE, Cai SP, Vichinsky EP, Olivieri NF.

N Engl J Med. 1993 Jan 14;328(2):81-6.

4.

Reduction of the clinical severity of sickle cell/beta-thalassemia with hydroxyurea: the experience of a single center in Greece.

Loukopoulos D, Voskaridou E, Kalotychou V, Schina M, Loutradi A, Theodoropoulos I.

Blood Cells Mol Dis. 2000 Oct;26(5):453-66.

PMID:
11112383
5.

Combination therapy of erythropoietin, hydroxyurea, and clotrimazole in a beta thalassemic mouse: a model for human therapy.

de Franceschi L, Rouyer-Fessard P, Alper SL, Jouault H, Brugnara C, Beuzard Y.

Blood. 1996 Feb 1;87(3):1188-95.

6.

Induction of fetal hemoglobin synthesis with recombinant human erythropoietin in anemic patients with heterozygous beta-thalassemia during pregnancy.

Breymann C, Fibach E, Visca E, Huettner C, Huch A, Huch R.

J Matern Fetal Med. 1999 Jan-Feb;8(1):1-7.

PMID:
10052837
7.

A recombinant human hemoglobin with anti-sickling properties greater than fetal hemoglobin.

Levasseur DN, Ryan TM, Reilly MP, McCune SL, Asakura T, Townes TM.

J Biol Chem. 2004 Jun 25;279(26):27518-24. Epub 2004 Apr 14.

8.

Extended therapy with intravenous arginine butyrate in patients with beta-hemoglobinopathies.

Sher GD, Ginder GD, Little J, Yang S, Dover GJ, Olivieri NF.

N Engl J Med. 1995 Jun 15;332(24):1606-10.

9.

Reference values and hematologic changes from birth to 5 years in patients with sickle cell disease. Cooperative Study of Sickle Cell Disease.

Brown AK, Sleeper LA, Miller ST, Pegelow CH, Gill FM, Waclawiw MA.

Arch Pediatr Adolesc Med. 1994 Aug;148(8):796-804.

PMID:
7519102
10.

Hydroxyurea therapy in thalassemia.

Loukopoulos D, Voskaridou E, Stamoulakatou A, Papassotiriou Y, Kalotychou V, Loutradi A, Cozma G, Tsiarta H, Pavlides N.

Ann N Y Acad Sci. 1998 Jun 30;850:120-8.

PMID:
9668534
11.

Improvement of erythropoiesis in beta-thalassemic mice by continuous erythropoietin delivery from muscle.

Bohl D, Bosch A, Cardona A, Salvetti A, Heard JM.

Blood. 2000 May 1;95(9):2793-8.

12.

Short survival of phosphatidylserine-exposing red blood cells in murine sickle cell anemia.

de Jong K, Emerson RK, Butler J, Bastacky J, Mohandas N, Kuypers FA.

Blood. 2001 Sep 1;98(5):1577-84.

13.

Oral sodium phenylbutyrate therapy in homozygous beta thalassemia: a clinical trial.

Collins AF, Pearson HA, Giardina P, McDonagh KT, Brusilow SW, Dover GJ.

Blood. 1995 Jan 1;85(1):43-9.

14.

Therapeutic hemoglobin levels after gene transfer in β-thalassemia mice and in hematopoietic cells of β-thalassemia and sickle cells disease patients.

Breda L, Casu C, Gardenghi S, Bianchi N, Cartegni L, Narla M, Yazdanbakhsh K, Musso M, Manwani D, Little J, Gardner LB, Kleinert DA, Prus E, Fibach E, Grady RW, Giardina PJ, Gambari R, Rivella S.

PLoS One. 2012;7(3):e32345. doi: 10.1371/journal.pone.0032345. Epub 2012 Mar 27.

15.

Second generation knockout sickle mice: the effect of HbF.

Fabry ME, Suzuka SM, Weinberg RS, Lawrence C, Factor SM, Gilman JG, Costantini F, Nagel RL.

Blood. 2001 Jan 15;97(2):410-8.

16.
17.

Pharmacological induction of fetal hemoglobin in sickle cell disease and beta-thalassemia.

Atweh GF, Loukopoulos D.

Semin Hematol. 2001 Oct;38(4):367-73. Review.

PMID:
11605172
18.

High expression of human beta S- and alpha-globins in transgenic mice: hemoglobin composition and hematological consequences.

Fabry ME, Nagel RL, Pachnis A, Suzuka SM, Costantini F.

Proc Natl Acad Sci U S A. 1992 Dec 15;89(24):12150-4.

19.

A second generation transgenic mouse model expressing both hemoglobin S (HbS) and HbS-Antilles results in increased phenotypic severity.

Fabry ME, Sengupta A, Suzuka SM, Costantini F, Rubin EM, Hofrichter J, Christoph G, Manci E, Culberson D, Factor SM, Nagel RL.

Blood. 1995 Sep 15;86(6):2419-28.

20.

Concurrent sickle-cell anemia and alpha-thalassemia: effect on severity of anemia.

Embury SH, Dozy AM, Miller J, Davis JR Jr, Kleman KM, Preisler H, Vichinsky E, Lande WN, Lubin BH, Kan YW, Mentzer WC.

N Engl J Med. 1982 Feb 4;306(5):270-4.

PMID:
6172710
Items per page

Supplemental Content

Write to the Help Desk